Arcellx, Inc. (ACLX) Insider Trading Activity
NASDAQ$58.78
Market Cap
$3.24B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
403 of 877
Rank in Industry
232 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ACLX Insider Trading Activity
ACLX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $32,194,567 | 49 | 100 |
Related Transactions
| Gilson Michelle | CHIEF FINANCIAL OFFICER | 0 | $0 | 9 | $6.11M | $-6.11M |
| Elghandour Rami | SEE REMARKS | 0 | $0 | 5 | $7.01M | $-7.01M |
| Patel Kavita | director | 0 | $0 | 20 | $8.95M | $-8.95M |
| Heery Christopher | CHIEF MEDICAL OFFICER | 0 | $0 | 15 | $10.13M | $-10.13M |
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Activity of Arcellx, Inc.
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $32.19M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $91.25M and sold $68.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
List of Insider Buy and Sell Transactions, Arcellx, Inc.
| 2025-04-29 | Sale | Patel Kavita | director | 1,500 0.0027% | $64.20 | $96,300 | -9.39% | |
| 2025-04-08 | Sale | Patel Kavita | director | 1,500 0.0028% | $57.50 | $86,250 | +13.68% | |
| 2025-03-18 | Sale | Patel Kavita | director | 1,500 0.0028% | $71.64 | $107,460 | -10.48% | |
| 2025-02-26 | Sale | Elghandour Rami | SEE REMARKS | 38,300 0.0727% | $62.02 | $2.38M | +6.59% | |
| 2025-02-25 | Sale | Patel Kavita | director | 1,500 0.0027% | $63.16 | $94,740 | +2.41% | |
| 2025-02-24 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 10,155 0.0188% | $63.79 | $647,773 | +1.30% | |
| 2025-02-04 | Sale | Patel Kavita | director | 1,500 0.0028% | $64.57 | $96,855 | -5.26% | |
| 2025-01-14 | Sale | Patel Kavita | director | 1,500 0.0028% | $65.87 | $98,801 | +0.17% | |
| 2025-01-08 | Sale | Elghandour Rami | SEE REMARKS | 13,837 0.0259% | $73.69 | $1.02M | -10.35% | |
| 2025-01-08 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 3,553 0.0066% | $73.69 | $261,831 | -10.35% | |
| 2025-01-08 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 3,997 0.0075% | $73.69 | $294,551 | -10.35% | |
| 2025-01-07 | Sale | Elghandour Rami | SEE REMARKS | 16,474 0.03% | $75.53 | $1.24M | -15.90% | |
| 2025-01-07 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 4,230 0.0077% | $75.53 | $319,485 | -15.90% | |
| 2025-01-07 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 14,012 0.0255% | $75.68 | $1.06M | -15.90% | |
| 2025-01-06 | Sale | Elghandour Rami | SEE REMARKS | 15,111 0.0287% | $77.17 | $1.17M | -13.60% | |
| 2025-01-06 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $77.17 | $229,571 | -13.60% | |
| 2025-01-06 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 5,621 0.0107% | $77.17 | $433,755 | -13.60% | |
| 2025-01-03 | Sale | Elghandour Rami | SEE REMARKS | 15,112 0.0284% | $79.55 | $1.2M | -18.08% | |
| 2025-01-03 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $79.55 | $236,656 | -18.08% | |
| 2025-01-03 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 5,622 0.0106% | $79.55 | $447,219 | -18.08% |
Total: 102
*Gray background shows transactions not older than one year
Insider Historical Profitability
29%
| Elghandour Rami | SEE REMARKS | 149186 0.2707% | $8.77M | 0 | 12 | |
| Heery Christopher | CHIEF MEDICAL OFFICER | 37486 0.068% | $2.2M | 0 | 37 | |
| Gilson Michelle | CHIEF FINANCIAL OFFICER | 9582 0.0174% | $563,229.96 | 0 | 13 | |
| Patel Kavita | director | 0 0% | $0 | 0 | 20 | |
| New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.2404% | $396.49M | 2 | 0 | +40.21% |
| Novo Holdings A/S | 10 percent owner | 4016878 7.2893% | $236.11M | 1 | 0 | +6.58% |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 3.0101% | $97.5M | 1 | 1 | +6.58% |
| Carroll Jill | director | 1479148 2.6842% | $86.94M | 1 | 6 | +6.58% |
| SANDELL SCOTT D | director | 0 0% | $0 | 0 | 2 | |
| BASKETT FOREST | director | 0 0% | $0 | 1 | 1 | +73.84% |
| Florence Anthony A. Jr. | director | 0 0% | $0 | 0 | 1 | |
| Makhzoumi Mohamad | director | 0 0% | $0 | 0 | 1 | |
| Ware Olivia C | director | 0 0% | $0 | 0 | 2 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$11,588,217 | 69 | 42.07% | $2.97B | |
$42,463,802 | 57 | 17.85% | $3.58B | |
$140,165,669 | 33 | 85.24% | $2.46B | |
$1,275,975,557 | 32 | 19.44% | $3.73B | |
$11,859,102 | 17 | 18.62% | $3.7B | |
$128,181,928 | 16 | 18.84% | $2.88B | |
$74,605,681 | 14 | 47.06% | $3.35B | |
$57,686,748 | 13 | 21.11% | $3.65B | |
$177,517,505 | 13 | 16.65% | $3.1B | |
$91,269,919 | 12 | 12.86% | $2.93B | |
$70,151,579 | 12 | 22.57% | $2.9B | |
$11,898,979 | 10 | 54.58% | $3.77B | |
$35,908,794 | 10 | 126.31% | $2.76B | |
$1,711,150 | 9 | 31.59% | $3.19B | |
$55,713,031 | 8 | -0.36% | $2.51B | |
$4,623,072 | 7 | 11.07% | $3.37B | |
Arcellx, Inc. (ACLX) | $182,500,000 | 6 | 29.00% | $3.24B |
$14,400,000 | 5 | 41.34% | $3.47B | |
$36,900,000 | 3 | -9.12% | $3.66B |
ACLX Institutional Investors: Active Positions
| Increased Positions | 112 | +47.66% | 13M | +24.95% |
| Decreased Positions | 104 | -44.26% | 4M | -8.04% |
| New Positions | 43 | New | 8M | New |
| Sold Out Positions | 36 | Sold Out | 2M | Sold Out |
| Total Postitions | 243 | +3.4% | 60M | +16.91% |
ACLX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $521,557.00 | 14.47% | 7.96M | +1M | +22.8% | 2024-12-31 |
| Gilead Sciences, Inc. | $440,549.00 | 12.22% | 6.72M | +7M | New | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $286,558.00 | 7.95% | 4.37M | +371,601 | +9.29% | 2024-12-31 |
| Blackrock, Inc. | $260,074.00 | 7.21% | 3.97M | +113,548 | +2.95% | 2025-03-31 |
| Nea Management Company, Llc | $245,502.00 | 6.81% | 3.75M | 0 | 0% | 2024-12-31 |
| Perceptive Advisors Llc | $228,041.00 | 6.33% | 3.48M | -409,781 | -10.54% | 2024-12-31 |
| Vanguard Group Inc | $218,288.00 | 6.06% | 3.33M | +867,996 | +35.25% | 2024-12-31 |
| Ra Capital Management, L.P. | $182,709.00 | 5.07% | 2.79M | +935,848 | +50.55% | 2024-12-31 |
| Sr One Capital Management, Lp | $153,822.00 | 4.27% | 2.35M | 0 | 0% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $139,053.00 | 3.86% | 2.12M | +220,711 | +11.61% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.